- Home
- RYAN vs MIRM Comparison
RYAN vs MIRM Comparison
Compare RYAN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RYAN | MIRM |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.7B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RYAN | MIRM |
|---|---|---|
| Price | $30.67 | $97.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $50.88 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.9M | 480.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,051,126,000.00 | $19,138,000.00 |
| Revenue This Year | $15.78 | $26.22 |
| Revenue Next Year | $12.49 | $22.04 |
| P/E Ratio | $86.72 | ★ N/A |
| Revenue Growth | ★ 21.28 | N/A |
| 52 Week Low | $31.50 | $40.00 |
| 52 Week High | $72.50 | $109.28 |
Technical Indicators
Market Signals| Indicator | RYAN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 57.40 |
| Support Level | N/A | $85.35 |
| Resistance Level | $38.61 | $98.03 |
| Average True Range (ATR) | 1.35 | 2.99 |
| MACD | -0.31 | 0.15 |
| Stochastic Oscillator | 8.85 | 83.45 |
Price Performance
Historical ComparisonAbout RYAN Ryan Specialty Holdings Inc.
Ryan Specialty Holdings Inc is an international specialty insurance intermediary providing specialty products, solutions, and services for insurance brokers, agents, and carriers. The company offers wholesale insurance brokerage and delegated underwriting authority products and services, including distribution, underwriting, product development, administration, and risk management. Its expertise spans property, casualty, professional lines, transportation, personal lines, workers compensation, and employee benefits insurance, across traditional insurance and alternative risk solutions. The company operates in the United States and foreign markets, with the majority of revenue generated from the United States.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.